Novo Nordisk applies for label extension for diabetes treatment

Novo Nordisk will now also apply to the EU for a new and higher dose of the drug Ozempic, which is has already been approved for treating type 2 diabetes.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR

Novo Nordisk plans to expand its selection of doses in which the firm may sell the diabetes drug Ozempic. Recently, this resulted in an application to the European Medicines Agency for extending the current label, according to the company's press announcement.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading